MIMEDX to Acquire Sanara MedTech in $350 Million Merger

InMed Pharmaceuticals to Merge with Mentari Therapeutics in $290M All-Stock Deal

May 20, 2026

Biotechnology

InMed Pharmaceuticals (NASDAQ: INM) entered into a definitive all-stock merger agreement with privately held Mentari Therapeutics, creating a publicly traded migraine-focused biotech under the Mentari name. The transaction is supported by an oversubscribed $290 million private placement led by Fairmount to fund operations through 2028.

Merck & Co. (Merck Sharp & Dohme) Acquires Cidara Therapeutics

January 8, 2026

Biotechnology

Merck Sharp & Dohme LLC (Merck & Co., Inc.) completed its cash tender offer and follow-on merger to acquire Cidara Therapeutics, Inc. for $221.50 per share, valuing the deal at about $9.2 billion. The acquisition adds Cidara’s late-stage, long-acting, strain-agnostic influenza antiviral candidate CD388 to Merck’s respiratory pipeline.

Day One Biopharmaceuticals Acquires Mersana Therapeutics

January 6, 2026

Healthcare Services

Day One Biopharmaceuticals acquired Mersana Therapeutics in a deal announced as a tender offer for all outstanding shares at $25 per share in cash plus a contingent value right (CVR) per share for potential milestone payments. The acquisition adds Mersana’s clinical-stage ADC emiltatug ledadotin (Emi-Le) targeting adenoid cystic carcinoma (ACC) to Day One’s oncology pipeline.

CorMedix Acquires Melinta Therapeutics for $300 Million

August 7, 2025

Biotechnology

CorMedix Inc. has entered into a definitive agreement to acquire Melinta Therapeutics, paying $300 million upfront (including $260 million cash and $40 million in CorMedix equity to Melinta shareholders), plus up to $25 million in a regulatory milestone and tiered royalties. The deal is expected to close in September, subject to customary closing conditions and U.S. regulatory approval.

Salona Global Medical Device Corp. Acquires Simbex, LLC

September 30, 2021

Medical Devices

Salona Global Medical Device Corporation (SGMD) acquired Simbex, LLC, an IP-driven medical device design and product company that generated approximately US$8.0 million in 2020 revenue. The acquisition is intended to expand SGMD’s recovery-medicine product portfolio, leverage manufacturing capabilities, and increase annualized run-rate revenues to over $24 million.

Midatech Pharma to Acquire DARA BioSciences

June 4, 2015

Pharmaceuticals

Midatech Pharma PLC entered into a merger agreement to acquire DARA BioSciences, with DARA shareholders receiving Midatech ordinary shares via ADRs and a contingent value right (CVR). The deal gives Midatech a U.S. commercial footprint and an expanded oncology supportive-care portfolio; closing was expected in Q3/Q4 2015 subject to customary conditions and ADR listing.